The manufacturer of the specific Tofacent 5 mg product is Incepta Pharmaceuticals Ltd.
This product-specific question should be kept separate from the documented history of tofacitinib and the XELJANZ reference product.
Tofacitinib developer
Pfizer developed tofacitinib, and the medicine became associated with the XELJANZ brand. XELJANZ received its initial U.S. approval in 2012.
Reference-product relationship
The current U.S. XELJANZ label is associated with Pfizer Laboratories Div Pfizer Inc.
In the EU, the EMA identifies Pfizer Europe MA EEIG as the marketing authorization holder for Xeljanz.
Manufacturer versus originator
A developer of an active ingredient does not necessarily manufacture every subsequent product containing that ingredient.
For Tofacent, these roles must be distinguished:
Official company information
Pfizer’s corporate website provides information about the company and its pharmaceutical operations. Pfizer official website
This should not be interpreted as evidence that Pfizer manufactures the specific Tofacent product.